|
Synonyms: E6071 | KANAb071
Compound class:
Antibody
Comment: GSK3050002 is a humanized IgG1κ antibody with high binding affinity to the human chemokine, CCL20. This biologic is being developed by GlaxoSmithKline in collaboration with Morphotek, based on a non-humanized antibody originally identified by KAN Research Institute, Inc., a subsidiary of Eisai Co., Ltd.
|
| No information available. |
Summary of Clinical Use  |
| Phase 1 clinical study in healthy subjects (NCT01984047) revealed no major safety concerns, and provided proof-of-concept for this mechanism of preventing recruitment of CCR6+ cells to inflammatory sites [1]. A Phase 1 study in psoriatic arthritis (NCT02671188) is registered with ClinicalTrials.gov, but is not yet recruiting patients. |
| Mechanism Of Action and Pharmacodynamic Effects |
| GSK3050002 down-modulates the CCL20/CCR6 interaction and inhibits recruitment of CCR6+ cells to inflammatory sites [1]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT01984047 | Single Dose Escalation Trial to Evaluate the Safety, Tolerability Pharmacokinetics and Pharmacodynamics of GSK3050002 | Phase 1 Interventional | GlaxoSmithKline | ||
| NCT02671188 | A Study to Evaluate the Safety, Mode of Action and Clinical Efficacy of GSK3050002 in Subjects With Psoriatic Arthritis | Phase 1 Interventional | GlaxoSmithKline | ||
